Literature DB >> 9083163

Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.

E Tartour1, L Deneux, V Mosseri, C Jaulerry, F Brunin, D Point, P Validire, B Dubray, W H Fridman, J Rodriguez.   

Abstract

BACKGROUND: The diagnosis and follow-up of head and neck carcinoma patients are based exclusively on clinical staging, which cannot always predict clinical outcome accurately. Because oral squamous cell carcinomas produce interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha and express IL-2 receptors, the authors assessed the prognostic value of the serum levels of these markers.
METHODS: Serum levels of IL-6, TNF-alpha, soluble IL-2 receptors (s-IL-2-R), and acute phase proteins were measured at the time of diagnosis in a prospective study of 85 patients with primary squamous cell carcinoma of the head and neck. The influence of each clinical and laboratory parameter on locoregional control and survival was analyzed.
RESULTS: At presentation, a relationship was observed between advanced tumor (T) classification and high serum levels of CRP (P = 0.0015) and s-IL-2-R (P < 0.05). A high lymph node (N) classification was significantly associated with elevated serum IL-6 (P = 0.01) and CRP levels (P = 0.0002). In the univariate analysis, T classification, N classification, performance status, Prognostic Inflammatory and Nutritional Index, and serum s-IL-2-R level were significantly correlated with both locoregional control and survival. Multivariate analysis showed that the only significant prognostic factors related independently to locoregional control were N classification (P = 0.02) and serum s-IL-2-R level (P = 0.02). In a Cox multivariate analysis, serum s-IL-2-R level was found to be the most predictive factor of survival (P = 0.0001).
CONCLUSIONS: This study shows that serum s-IL-2-R level at the time of diagnosis represents a new independent prognostic variable for predicting the risk of locoregional recurrence and survival for patients with head and neck squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083163

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma.

Authors:  M Grimm; M Lazariotou
Journal:  Med Oncol       Date:  2011-08-19       Impact factor: 3.064

2.  C-reactive protein as an acute phase protein in cancer patients.

Authors:  Murat Bolayirli; Hande Turna; Timur Orhanoğlu; Resat Ozaras; Mahmut Ilhan; Mustafa Ozgüroğlu
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

Authors:  David Loose; Alberto Signore; Ludovicus Staelens; Katia Vanden Bulcke; Hubert Vermeersch; Rudi Andre Dierckx; Elena Bonanno; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

4.  Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.

Authors:  N El Houda Agueznay; C Badoual; S Hans; A Gey; B Vingert; S Peyrard; F Quintin-Colonna; P Ravel; P Bruneval; S Roncelin; B Lelongt; J Bertoglio; W H Fridman; D Brasnu; E Tartour
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

5.  Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.

Authors:  B Nakata; K H Chung; Y Kato; Y Yamashita; A Inui; Y Arimoto; K Maeda; N Onoda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.

Authors:  Harlinde De Schutter; Willy Landuyt; Erik Verbeken; Laurence Goethals; Robert Hermans; Sandra Nuyts
Journal:  BMC Cancer       Date:  2005-04-25       Impact factor: 4.430

7.  Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Authors:  Meriem Hasmim; Cécile Badoual; Philippe Vielh; Françoise Drusch; Virginie Marty; Agnès Laplanche; Mariana de Oliveira Diniz; Hélène Roussel; Eléonore De Guillebon; Stéphane Oudard; Stéphane Hans; Eric Tartour; Salem Chouaib
Journal:  BMC Cancer       Date:  2013-12-11       Impact factor: 4.430

Review 8.  Interleukin-6 role in head and neck squamous cell carcinoma progression.

Authors:  Moaz M Choudhary; Thomas J France; Theodoros N Teknos; Pawan Kumar
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2016-07-20

Review 9.  Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring.

Authors:  Araceli Diez-Fraile; Joke De Ceulaer; Charlotte Derpoorter; Christophe Spaas; Tom De Backer; Philippe Lamoral; Johan Abeloos; Tim Lammens
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

10.  Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma.

Authors:  Hsuan-Ho Chen; Hung-Ming Wang; Kang-Hsing Fan; Chien-Yu Lin; Tzu-Chen Yen; Chun-Ta Liao; I-How Chen; Chung-Jan Kang; Shiang-Fu Huang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.